# A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

> **NCT03026166** · PHASE1,PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 42 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Rovalpituzumab tesirine

## Key facts

- **NCT ID:** NCT03026166
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-30
- **Primary completion:** 2019-07-03
- **Final completion:** 2019-07-03
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2.
- **Last updated:** 2020-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03026166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03026166, "A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03026166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*